In this 26-week , randomised , double-blind , placebo-controlled trial , adults ( 25 years old ) with early-stage to mid-stage Huntington 's disease were randomly assigned ( 1:1:1 ) by a centralised interactive response system to once daily PBT2 250 mg , PBT2 100 mg , or placebo .